Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(3.07) per share which missed the analyst consensus estimate of $(2.15) by 42.79 percent. The company reported quarterly sales of $1.269 million which beat the analyst consensus estimate of $333.333 thousand by 280.70 percent. This is a 41.09 percent decrease over sales of $2.154 million the same period last year.
Aligos Therapeutics Q3 2024 GAAP EPS $(3.07) Misses $(2.15) Estimate, Sales $1.269M Beat $333.333K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated